BIND Therapeutics (BIND) Tops Q3 EPS by 3c; Sees Milestone Payment from AstraZeneca in Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BIND Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 2, 2015 7:30 AM ESTiNSITE 1 trial on track for stage 1 data by year-end; iNSITE 2 on track for stage 1 data in 1H 2016 for treatment of rare tumor types
Progress continues in developing next-generation Accurin products for multiple therapeutic areas
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results and business highlights for the third quarter ended September 30, 2015. Management will host a conference call today at 8:30 a.m. ET to provide a business update and review the... More
